BIO-Europe Spring® 2017: Imanova trims Phase I and IIa trial timelines and costs

April 25, 2017

Dr. Kevin Cox, CEO of Imanova, the UK-based translational biomedical imaging company, explains to Scrip’s Mike Ward how his company can help biotechs and pharma firms cut the cost of Phase I and IIa trials by GBP 2 million (USD 2.6 million) while shaving six months of the time to complete the program. He explains how the company, which was originally GSK’s imaging center and was spun out in 2011, helps clients determine whether a candidate drug gets into the tissue, hits the right target at optimal levels by providing an end-to-end service in PET and MR imaging studies for drug development. Services include experimental design, radio-chemistry, preclinical and clinical imaging, analysis and reporting.

 

Click here for more coverage of the activities held during BIO-Europe Spring

Previous Video
BIO-Europe Spring® 2017: Korean pharma spawns US cancer biotech startup
BIO-Europe Spring® 2017: Korean pharma spawns US cancer biotech startup

HanAll, a Korean generics and drug reformulation business, has established a US biotech based on research i...

Next Article
VIDEO: Innovation in an uncertain world
VIDEO: Innovation in an uncertain world

How are cutting-edge biotech companies trying to compete in a global marketplace dealing with drug-price an...